Английская Википедия:Center for Genetic Engineering and Biotechnology
Шаблон:Short description Шаблон:Infobox government agency The Center for Genetic Engineering and Biotechnology (Шаблон:Lang-es, CIGB) is a research institute in Havana, Cuba.
Founding
In 1982, the United Nations Industrial Development Organization (UNIDO) offered grant funding via a competitive application process to facilitate biotechnology development in the Third World.[1]Шаблон:Rp Cuba sought, but did not receive funding, which instead was awarded to a joint project proposed by India and Italy.[1]Шаблон:Rp Cuba nonetheless proceeded with the development of a biotechnology research institution using its own funds, CIGB.[1]Шаблон:Rp
Activity
In 2006, CIGB developed the Heberprot-P, which is used to treat foot ulcers.[2] Its use results in rapid wound healing and a 75% decrease in amputations among diabetics with foot ulcers.[2]
As of 2017, CIGB had 1,600 employees and sold 21 products internationally.[1]Шаблон:Rp
As of 2020, CIGB had two joint ventures with China.[1]Шаблон:Rp
It is responsible for creating the Abdala vaccine.[3][4][5]
The Centre developed the COVID-19 vaccine Mambisa, which is in the final stages of clinical trials.[6]
See also
References
External links
Шаблон:Med-company-stub
Шаблон:Cuba-stub
